This result may suggest that the anti‐tumor targeting of PTPRN2 not only requires the inhibition of PTPRN2 at the protein level but also the abnormal transcription of PTPRN2 mediated by upstream HOXD13. This evidence concerns the gene PTPRN2 and neoplasm.